Caffeine Has Similar Pharmacokinetics and Behavioral Effects via the IP and PO Routes of Administration

Caffeine administered intraperitoneally (i.p.) or orally (p.o.) decreased the reinforcement rate and increased the nonreinforced response rate in a dose-related fashion under a differential reinforcement of low rate schedule (DRL 45-s) in 3-h sessions. These effects were similar following both routes of caffeine administration. The parallel pharmacokinetics for i.p. and p.o. caffeine were each determined and related to the respective effects of caffeine on reinforcement rate. Serum caffeine concentrations were similar across the session after the absorption phase for a given dose. Consequently, the effect remained in approximately the same range within a dose, and no single dose possessed a full concentration-effect relation for the two routes. The effects of i.p. and p.o. caffeine on reinforcement rate plateaued at doses higher than 40 mg/kg, which produced a serum caffeine concentration of approximately 25 microg/ml regardless of the route of administration. The EC50 values were 7.34 and 9.93 microg/ml for i.p. and p.o. caffeine, respectively. This study as well as our previous studies demonstrated that the i.p. route is dependable for studying caffeine dose response relations but not for studying other drugs (e.g., midazolam). The possible mechanism accounting for this difference is discussed.

[1]  J. Axelrod,et al.  The fate of caffeine in man and a method for its estimation in biological material. , 1953, The Journal of pharmacology and experimental therapeutics.

[2]  J. Falk,et al.  Tolerance to oral and IP caffeine: Locomotor activity and pharmacokinetics , 1994, Pharmacology Biochemistry and Behavior.

[3]  Charles J. Meliska,et al.  Caffeine and nicotine: Differential effects on ambulation, rearing and wheelrunning , 1984, Pharmacology Biochemistry and Behavior.

[4]  J. Falk,et al.  Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and caffeine. , 1997, The Journal of pharmacology and experimental therapeutics.

[5]  Stephen G. Holtzman,et al.  Tolerance to behavioral effects of caffeine in rats , 1988, Pharmacology Biochemistry and Behavior.

[6]  G. Marek,et al.  Effects of caffeine and PD 116,600 on the differential-reinforcement-of-low rate 72-S (DRL 72-S) schedule of reinforcement , 1993, Pharmacology Biochemistry and Behavior.

[7]  G. K. Mumford,et al.  Qualitative differences in the discriminative stimulus effects of low and high doses of caffeine in the rat. , 1991, The Journal of pharmacology and experimental therapeutics.

[8]  W. Parsons,et al.  Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene. , 1977, Life sciences.

[9]  J. Falk,et al.  Dose-dependent surmountability of locomotor activity in caffeine tolerance , 1995, Pharmacology Biochemistry and Behavior.

[10]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[11]  M. Danhof,et al.  Pharmacokinetic‐pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration , 1991, British journal of pharmacology.

[12]  M. Bonati,et al.  Interspecies Comparison of Caffeine Disposition , 1984 .

[13]  W. Burkard,et al.  Pharmacology of midazolam. , 1981, Arzneimittel-Forschung.

[14]  Dennis Webb,et al.  Effects of caffeine on DRL performance in the mouse , 1978, Pharmacology Biochemistry and Behavior.

[15]  P. Heizmann,et al.  Excretion and metabolism of 14C-midazolam in humans following oral dosing. , 1981, Arzneimittel-Forschung.

[16]  M. Newland,et al.  Oral caffeine consumption by rats: The role of flavor history, concentration, concurrent food, and an adenosine agonist , 1992, Pharmacology Biochemistry and Behavior.

[17]  J. Richards,et al.  DRL interresponse-time distributions: quantification by peak deviation analysis. , 1993, Journal of the experimental analysis of behavior.

[18]  P Heizmann,et al.  Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.

[19]  J. Falk,et al.  Independent interaction of alprazolam and caffeine under chronic dose regimens on differential reinforcement of low-rate (DRL 45-s) performance , 1997, Psychopharmacology.

[20]  J. Falk,et al.  Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam , 1991, Pharmacology Biochemistry and Behavior.